for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Spark Therapeutics Inc

ONCE.O

Latest Trade

100.99USD

Change

0.87(+0.87%)

Volume

365,668

Today's Range

99.90

 - 

101.50

52 Week Range

34.53

 - 

114.20

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
100.12
Open
100.58
Volume
365,668
3M AVG Volume
8.90
Today's High
101.50
Today's Low
99.90
52 Week High
114.20
52 Week Low
34.53
Shares Out (MIL)
38.49
Market Cap (MIL)
3,853.24
Forward P/E
-17.41
Dividend (Yield %)
--

Latest Developments

More

Platelet BioGenesis Raises $26 Mln In Series A-1 Financing

Roche CEO says committed to Spark deal, portfolio "without any question"

Roche Does Not Believe Spark Takeover Deal In Doubt

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Spark Therapeutics Inc

Spark Therapeutics, Inc. is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial. Its product investigational candidate, voretigene neparvovec, is intended to treat a genetic blinding condition or inherited retinal disease (IRD). The programs targeting hematologic disorders include SPK-FIX, for which the lead product candidate, SPK-9001, is in a Phase I/II clinical trial for the treatment of hemophilia B, as well as SPK-FVIII for the treatment of hemophilia A. In its SPK-FVIII program for the treatment of hemophilia A, the Company has initiated a dose-escalating Phase I/II clinical trial for its lead product candidate, SPK-8011.

Industry

Biotechnology & Drugs

Contact Info

3737 Market St Ste 1300

+1.212.7906248

http://www.sparktx.com/

Executive Leadership

Steven M. Altschuler

Independent Chairman of the Board

Katherine A. High

President, Head of Research and Development and Director

Jeffrey D. Marrazzo

Chief Executive Officer, Co-Founder, Director

Stephen W. Webster

Chief Financial Officer

Federico Mingozzi

Chief Scientific Officer

Key Stats

3.00 mean rating - 14 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.1K

2019(E)

0.1K
EPS (USD)

2016

-4.290

2017

-7.630

2018

-2.110

2019(E)

-5.749
Price To Earnings (TTM)
--
Price To Sales (TTM)
66.28
Price To Book (MRQ)
9.59
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
12.64
LT Debt To Equity (MRQ)
10.69
Return on Investment (TTM)
-33.13
Return on Equity (TTM)
-30.35

Latest News

Latest News

Roche lifts 2019 sales view again as Chinese demand soars

Swiss drugmaker Roche <ROG.S> lifted its 2019 sales target on Wednesday for the third time this year, helped by newer medicines and as China bought more cancer drugs to treat a disease blamed for a quarter of the nation's annual deaths.

Roche, Spark again extend $4.3 billion takeover offer

Roche Holding <ROG.S> and Spark Therapeutics <ONCE.O> announced on Tuesday another extension of the Swiss drugmaker's $4.3 billion takeover offer for the U.S. gene therapy specialist as regulatory reviews continue.

Roche, Spark push back takeover deadline in $4.3 billion deal

Roche <ROG.S> and Spark Therapeutics <ONCE.O> agreed to extend the deadline for the Swiss drugmaker's $4.3 billion takeover bid for the U.S. gene therapy specialist, Roche said, adding it remains "fully committed" to a deal it sees closing this year.

BRIEF-Roche And Spark Therapeutics Receive Information Request From Federal Trade Commission

* ROCHE AND SPARK THERAPEUTICS, INC. RECEIVE REQUEST FOR ADDITIONAL INFORMATION FROM FTC UNDER HART-SCOTT-RODINO ACT AND ANNOUNCE EXTENSION OF TENDER OFFER FOR SHARES OF SPARK THERAPEUTICS, INC.

BRIEF-Spark Therapeutics Says Upon Termination Of Deal with Roche, Under Specified Circumstances, Co Will Be Required To Pay To Roche A Termination Fee Of $144 Mln

* SPARK THERAPEUTICS - UPON TERMINATION OF DEAL, UNDER SPECIFIED CIRCUMSTANCES, CO WILL BE REQUIRED TO PAY TO ROCHE A TERMINATION FEE OF $144 MILLION. Source text: (https://bit.ly/2TfvJRj) Further company coverage:

Roche to buy gene therapy specialist Spark in $4.3 bln deal

Roche on Monday said it will buy Spark Therapeutics in a transaction valued at $4.3 billion as the Swiss drugmaker builds its hemophilia portfolio and seeks to keep pace in gene therapy with rivals like Novartis.

BRIEF-Spark Therapeutics To Be Acquired By Roche For $4.8 Bln

* SPARK THERAPEUTICS ENTERS INTO DEFINITIVE MERGER AGREEMENT WITH ROCHE

Roche nearing $5 billion deal to acquire Spark Therapeutics: WSJ

Swiss drugmaker Roche Holding AG is nearing a deal to acquire U.S. biotechnology company Spark Therapeutics Inc, the Wall Street Journal reported on Saturday, citing people familiar with the matter.

Roche nearing $5 billion deal to acquire Spark Therapeutics -WSJ

Swiss drugmaker Roche Holding AG is nearing a deal to acquire U.S. biotechnology company Spark Therapeutics Inc, the Wall Street Journal reported on Saturday, citing people familiar with the matter.

BRIEF-European Commission Approves Spark Therapeutics' Luxturna

* EUROPEAN COMMISSION APPROVES SPARK THERAPEUTICS' LUXTURNA® (VORETIGENE NEPARVOVEC), A ONE-TIME GENE THERAPY FOR INHERITED RETINAL DISEASE CAUSED BY CONFIRMED BIALLELIC RPE65 MUTATIONS Source text for Eikon: Further company coverage:

BRIEF-Spark Therapeutics Reports Q1 Loss Per Share Of $1.25

* SPARK THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND RECENT BUSINESS PROGRESS

BRIEF-Spark Therapeutics Says Entered Into Asset Purchase Agreement With Jazz Pharmaceuticals Ireland Ltd

* SPARK THERAPEUTICS SAYS ENTERED INTO ASSET PURCHASE AGREEMENT WITH JAZZ PHARMACEUTICALS IRELAND LIMITED - SEC FILING

BRIEF-Children's Hospital Of Philadelphia Foundation To Engage In Dialogue With Spark Therapeutics To Be Allowed To Designate At Least 1 Board Member

* CHILDREN'S HOSPITAL OF PHILADELPHIA FOUNDATION - TO ENGAGE IN DIALOGUE WITH SPARK THERAPEUTICS TO BE ALLOWED TO DESIGNATE AT LEAST 1 BOARD MEMBER

BRIEF-Spark Therapeutics Reports Cash And Cash Equivalents And Marketable Securities Of $540.2 Mln As Of Dec. 31, 2017

* SPARK THERAPEUTICS REPORTS 2017 FINANCIAL RESULTS AND RECENT BUSINESS PROGRESS

Spark licenses blindness gene therapy rights outside U.S. to Novartis

Spark Therapeutics Inc, whose breakthrough gene therapy to treat a rare form of blindness was approved by U.S. regulators in December, said on Wednesday that it had licensed rights to the drug outside the United States to Switzerland-based Novartis AG.

Spark licenses blindness gene therapy rights outside U.S. to Novartis

Spark Therapeutics Inc, whose breakthrough gene therapy to treat a rare form of blindness was approved by U.S. regulators in December, has licensed rights to the drug in markets outside the United States to Switzerland-based Novartis AG, it said on Wednesday.

BRIEF-Spark Therapeutics Enters Into Licensing, Supply Agreement For Investigational Voretigene Neparvovec Outside U.S.

* SPARK THERAPEUTICS ENTERS INTO A LICENSING AND SUPPLY AGREEMENT FOR INVESTIGATIONAL VORETIGENE NEPARVOVEC OUTSIDE THE U.S.

Spark's price for Luxturna blindness gene therapy too high: ICER

The proposed price for Spark Therapeutics Inc's <ONCE.O> groundbreaking one-time gene therapy for a rare form of blindness is far too high, an independent U.S. nonprofit organization that evaluates clinical and cost effectiveness of new medicines said on Friday.

CORRECTED-Spark's planned price for Luxturna gene therapy for rare blindness too high -ICER

The proposed price for Spark Therapeutics Inc's groundbreaking one-time gene therapy for a rare form of blindness is far too high, an independent U.S. nonprofit organization that evaluates clinical and cost effectiveness of new medicines said on Friday.

BRIEF-ICER Says Spark Therapeutics Gene Therapy Price Too High

* INSTITUTE FOR CLINICAL AND ECONOMIC REVIEW SAYS SPARK THERAPEUTICS LUXTURNA GENE THERAPY PRICE FAR TOO HIGH

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up